USPTO serial 90133236
FIBROBODIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 22, 2022
- Examiner
- DERBY, KAREN SHEREE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with FIBROBODIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
AMSTERDAM, NL
AMSTERDAM, NL
AMSTERDAM, NL
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Roberta S. Bren
Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.125 S. Royal St.Alexandria, VA 22314United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and peroral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and peroral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; Biochemical medicines for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposes, namely, for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for medical purposes; pharmaceutical substances and preparations for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; carrier excipients consisting of compounds that facilitate delivery of pharmaceutical preparations | ACTIVE | — |
| 042 | Pharmaceutical research services; conducting clinical trials for others relating to pharmaceuticals; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; scientific research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology | ACTIVE | — |
| 044 | Medical services, namely, in vitro analysis for medical and pharmaceutical use; Medical services, namely, in vitro testing for medical and pharmaceutical use; consultancy and information services provided via the Internet relating to pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LinXis B.V.
- Other trademarks owned by LinXis B.V.
- Other trademarks owned by LinXis B.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named FIBROBODIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 19, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 19, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 19, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 22, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 22, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 22, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 22, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 22, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 22, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 22, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 11, 2022 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Feb 11, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 18, 2022 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jan 18, 2022 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Oct 19, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 24, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 24, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 4, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 20, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 4, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 2, 2021 | ALIE | ASSIGNED TO LIE | — |
| Mar 4, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 27, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 26, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 27, 2020 | NWAP | NEW APPLICATION ENTERED | — |